Лечение больных множественной миеломой препаратом «Велкейд»

Войцеховский Валерий Владимирович, Ландышев Юрий Сергеевич, Есенин Владимир Васильевич et al. · Dalʹnevostočnyj medicinskij žurnal · 2009

Multiple myeloma (MM) is the malignant blood disease that is included into the group of paraproteinemic hemoblasto-ses. MM remains incurable disease. 20-40% of MM-sufferers are non sensitive to the chemotherapeutic treatment (primary resistance). All the patients in different periods of time acquire secondary resistance. Proteasome 26S plays a signifi cant role in the formation of growth resistance. At the time being, pro-teasome inhibitor «Velcade» (bortezomib) is widely used for treatment of resistant and relapsing forms of MM. This article describes an experience of hematological department of Amur regional clinical hospital in treatment of MM-patients using the abovementioned drug.

Cited by 0 works.

Authors